Literature DB >> 25498911

Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.

Ronald P Taylor1, Margaret A Lindorfer1.   

Abstract

A specialized form of trogocytosis occurs when Fcγ receptors on acceptor cells take up and internalize donor cell-associated immune complexes composed of specific monoclonal antibodies (mAbs) bound to target antigens on donor cells. This trogocytosis reaction, an example of antigenic modulation, has been described in recent clinical correlative studies and in vitro investigations for several mAbs used in cancer immunotherapy, including rituximab and ofatumumab. We discuss the impact of Fcγ-receptor-mediated trogocytosis on the efficacy of cancer immunotherapy and other mAb-based therapies.
© 2015 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25498911     DOI： 10.1182/blood-2014-10-569244

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  51 in total

1.  Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.

Authors:  Jonathan J Pinney; Fátima Rivera-Escalera; Charles C Chu; Hannah E Whitehead; Karl R VanDerMeid; Ashley M Nelson; Michelle C Barbeau; Clive S Zent; Michael R Elliott
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

2.  Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia.

Authors:  Etienne Crickx; Pascal Chappert; Aurélien Sokal; Sandra Weller; Imane Azzaoui; Alexis Vandenberghe; Guillaume Bonnard; Geoffrey Rossi; Tatiana Fadeev; Sébastien Storck; Jehane Fadlallah; Véronique Meignin; Etienne Rivière; Sylvain Audia; Bertrand Godeau; Marc Michel; Jean-Claude Weill; Claude-Agnès Reynaud; Matthieu Mahévas
Journal:  Sci Transl Med       Date:  2021-04-14       Impact factor: 17.956

3.  Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model.

Authors:  Sean R Stowell; C Maridith Arthur; Kathryn R Girard-Pierce; Harold C Sullivan; Manjula Santhanakrishnan; Prabitha Natarajan; Seema R Patel; Christopher A Tormey; James C Zimring; Jeanne E Hendrickson
Journal:  Haematologica       Date:  2015-07-16       Impact factor: 9.941

4.  Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.

Authors:  Amita Datta-Mannan; Johnny E Croy; Linda Schirtzinger; Stacy Torgerson; Matthew Breyer; Victor J Wroblewski
Journal:  MAbs       Date:  2016-07       Impact factor: 5.857

5.  Assaying How Phagocytic Success Depends on the Elasticity of a Large Target Structure.

Authors:  Megan Davis-Fields; Layla A Bakhtiari; Ziyang Lan; Kristin N Kovach; Liyun Wang; Elizabeth M Cosgriff-Hernandez; Vernita D Gordon
Journal:  Biophys J       Date:  2019-09-13       Impact factor: 4.033

6.  Six-packed antibodies punch better.

Authors:  Christoph Rader; Adrian Wiestner
Journal:  Haematologica       Date:  2019-09       Impact factor: 9.941

7.  In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.

Authors:  Sean P Arlauckas; Christopher S Garris; Rainer H Kohler; Maya Kitaoka; Michael F Cuccarese; Katherine S Yang; Miles A Miller; Jonathan C Carlson; Gordon J Freeman; Robert M Anthony; Ralph Weissleder; Mikael J Pittet
Journal:  Sci Transl Med       Date:  2017-05-10       Impact factor: 17.956

8.  Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation.

Authors:  Josée Golay; Rut Valgardsdottir; Gerta Musaraj; Damiano Giupponi; Orietta Spinelli; Martino Introna
Journal:  Blood       Date:  2019-01-17       Impact factor: 22.113

9.  Clinically significant anti-KEL RBC alloantibodies are transferred by breast milk in a murine model.

Authors:  M Santhanakrishnan; C A Tormey; P Natarajan; J Liu; J E Hendrickson
Journal:  Vox Sang       Date:  2016-03-07       Impact factor: 2.144

10.  Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Authors:  Martin Skarzynski; Carsten U Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E Marti; Katherine R Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.